IP Library Granted Patent US 9,066,782
Granted Patent B2
US 9,066,782 · App. 13/716,763 · Granted Jun 30, 2015

Ocular implant with therapeutic agents and methods thereof

Inventors: Hosheng Tu (Newport Coast, CA); Barbara A Niksch (Capistrano Beach, CA); David S Haffner (Mission Viejo, CA); Gregory T Smedley (Aliso Viejo, CA); Olav B Bergheim (Laguna Hills, CA); Morteza Gharib (Altadena, CA); Richard A. Hill (Irvine, CA); Thomas W. Burns (Dana Point, CA)
Assignee: Dose Medical Corporation
A61F9/00781A61F9/0017A61L27/54A61L2300/258A61L2300/41A61L2300/414A61L2300/416A61L2300/42A61L2430/16A61M27/002
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,066,782
App. No.
13/716,763
Granted
Jun 30, 2015
Kind
B2
Abstract

Implants and methods for treating ocular disorders are provided. One method involves introducing an implant into an anterior chamber of an eye. The implant is implanted into eye tissue adjacent the anterior chamber such that a proximal end of the implant resides in the anterior chamber following implantation. A therapeutic agent is eluted from the implant into the eye. Desirably, the release of the therapeutic agent from the implant is controlled. The controlled release of the therapeutic agent can be at a chosen rate and/or for a selected duration which can be episodic or periodic. The therapeutic agent can be an antiproliferative agent, an anti-inflammatory drug, or a compound for treating glaucoma or ocular hypertension.

Claims (22)

1. A method of treating an ocular disorder, comprising:

introducing an implant into an anterior chamber of an eye;

implanting the implant into eye tissue adjacent the anterior chamber such that a proximal end of the implant resides in the anterior chamber following implantation;

eluting a therapeutic agent from the implant into the eye; and

controlling release of the therapeutic agent from the implant,

wherein introducing an implant comprises introducing the implant into the anterior chamber such that at least a distal end of the implant is temporarily in the anterior chamber.

2. The method of claim 1 , wherein controlling release comprises controlling release of the therapeutic agent at a chosen rate.

3. The method of claim 2 , wherein the chosen rate is episodic or periodic.

4. The method of claim 1 , wherein controlling release comprises controlling release of the therapeutic agent for a selected duration.

5. The method of claim 4 , wherein the selected duration is episodic or periodic.

6. The method of claim 1 , wherein controlling release comprises controlling release of the therapeutic agent at a chosen rate and for a selected duration.

7. The method of claim 6 , wherein the chosen rate and/or the selected duration are episodic or periodic.

8. The method of claim 1 , wherein eluting a therapeutic agent from the implant comprises eluting the therapeutic agent into at least one of the anterior chamber, a physiologic outflow pathway of the eye, and a space adjacent a choroid of the eye.

9. The method of claim 1 , wherein the therapeutic agent comprises an antiproliferative agent or an anti-inflammatory drug.

10. The method of claim 1 , wherein the therapeutic agent comprises a compound for treating glaucoma or ocular hypertension.

11. The method of claim 1 , wherein the therapeutic agent is contained within the implant.

12. The method of claim 1 , wherein the therapeutic agent is coated on the implant.

13. The method of claim 1 , wherein introducing an implant into an anterior chamber of an eye involves forming an incision in corneal tissue.

14. The method of claim 1 , wherein introducing an implant into an anterior chamber of an eye involves forming an incision proximate a limbus of the eye.

15. The method of claim 1 , wherein introducing an implant into an anterior chamber of an eye involves forming a self sealing incision.

16. The method of claim 1 , wherein implanting the implant involves placing the implant in contact with a choroid of the eye.

17. The method of claim 1 , wherein the implant comprises at least one anchor.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 12, 2015
From: GLAUKOS CORPORATION
To: DOSE MEDICAL CORPORATION
Reel/Frame 035831/0429 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 19, 2015
From: HILL, RICHARD A.
To: GLAUKOS CORPORATION
Reel/Frame 035668/0613 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 19, 2015
From: BURNS, THOMAS W.
To: GLAUKOS CORPORATION
Reel/Frame 035727/0404 →
Continuity (14)
Continuation 12772889 · May 3, 2010
Continuation 10706300 · Nov 12, 2003
Continuation In Part 10395633 · Mar 21, 2003
Continuation 09549350 · Apr 14, 2000
Continuation In Part 10634213 · Aug 5, 2003
Continuation In Part 10118578 · Apr 8, 2002
Continuation In Part 10046137 · Nov 8, 2001
Provisional Application 60281973 · Apr 7, 2001
Provisional Application 60401166 · Aug 5, 2002
Provisional Application 60451226 · Feb 28, 2003
Provisional Application 60281247 · Apr 3, 2001
Provisional Application 60425911 · Nov 12, 2002
Provisional Application 60431918 · Dec 9, 2002
Related Publication 20140012177A1 · Jan 9, 2014